Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2012

View Archived Issues

New data support Tmprss6 as a therapeutic target for beta-thalassemia and hereditary hemochromatosis

U.S. researchers design novel heterodimeric targeting ligands

Ironwood Pharmaceuticals begins phase I trial of antianxiety drug candidate

Halozyme Therapeutics and Pfizer to develop recombinant human hyaluronidase biologics

Phase II TO-2061 trial in OCD does not meet primary endpoint

A new vaccine target identified for the treatment of parasitic Schistosomiasis

Novel alpha7 nAChR receptor agonist designed by Siena Biotech and Pfizer

Endo returns global rights for Urocidin

Novel diagnostic agents for AD patented by Nihon Medi-Physics

Catabasis Pharmaceuticals presents new GABA conjugates

Spectrum Pharmaceuticals' pivotal BELIEF trial meets primary endpoint

Novel agents for obesity disclosed by GlaxoSmithKline

Researchers at Merck & Co. patent new PDE10A inhibitors

Ranbaxy Laboratories presents new DPP IV inhibitor for the treatment of diabetes

The Wistar Institute divulges new EBNA-1 protein inhibitors

Two novel mutations identified in patient with cyclic neutropenia

Raptor Pharmaceutical provides update on NDA review for Procysbi

Recommendations presented by AAC on Ampligen for chronic fatigue syndrome

U.K. regulators set to approve Horizon Pharma's MAA for Duexis

Only For Children Pharmaceuticals withdraws MAA for Loulla

Cubist submits supplemental NDA to FDA for Entereg

FDA approves Juxtapid for homozygous familial hypercholesterolemia

A dual SYK/JAK inhibitor shows potential in animal models of arthritis and B-cell malignancies

Acorda Therapeutics completes acquisition of Neuronex

Sarepta Therapeutics enters into influenza trial agreement with the NIAID

Once-monthly formulation of antiosteoporotic agent approved in Japan

Results published from phase II trial of immunocytokine therapy in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...